Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders
Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced that preclinical studies on CTI-1601’s impact on gene expression and neurodegeneration will be showcased at the Gordon Research Conference on Neurobiology of Brain Disorders from August 7-12, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced that preclinical studies on CTI-1601’s impact on gene expression and neurodegeneration will be showcased at the Gordon Research Conference on Neurobiology of Brain Disorders from August 7-12, 2022. The poster, titled "Mitochondrial Protein Frataxin (FXN) promotes Expression of Neuronal Differentiation Markers," will be presented by David Bettoun, Ph.D., Vice President of Discovery and Non-clinical R&D. Larimar focuses on developing treatments for complex rare diseases, including Friedreich's ataxia.
Positive
- CTI-1601's preclinical studies may enhance understanding of its therapeutic potential for neurodegeneration.
- Presentation at a reputable conference may increase visibility and credibility among investors and scientists.
Negative
- None.
Details
News Market Reaction – LRMR
The recorded move for LRMR in the trading session of this news was -3.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BALA CYNWYD, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that preclinical studies evaluating CTI-1601’s effects on gene expression and neurodegeneration will be featured in a poster at the upcoming Gordon Research Conference on Neurobiology of Brain Disorders. The conference will take place August 7 – 12, 2022 at the Rey Don Jaime Grand Hotel in Castelldefels, Spain.
The poster, entitled, “Mitochondrial Protein Frataxin (FXN) promotes Expression of Neuronal Differentiation Markers: Effect of FXN Supplementation in a Model of Leukodystrophy,” will be available for viewing throughout the duration of the conference. The poster’s presenting author is David Bettoun, Ph.D., Vice President of Discovery and Non-clinical R&D, Larimar Therapeutics.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.